keyword
https://read.qxmd.com/read/38569939/engineered-interleukin-6-derived-cytokines-recruit-artificial-receptor-complexes-and-disclose-cntf-signaling-via-the-osmr
#21
JOURNAL ARTICLE
Puyan Rafii, Patricia Rodrigues Cruz, Julia Ettich, Christiane Seibel, Giacomo Padrini, Christoph Wittich, Alexander Lang, Patrick Petzsch, Karl Köhrer, Jens M Moll, Doreen M Floss, Jürgen Scheller
Ciliary neurotrophic factor (CNTF) activates cells via the non-signaling α-receptor CNTF receptor (CNTFR) and the two signaling β-receptors glycoprotein 130 (gp130) and leukemia inhibitory factor receptor (LIFR). The CNTF derivate, Axokine was protective against obesity and insulin resistance but clinical development was halted by the emergence of CNTF-antibodies. The chimeric cytokine IC7 used the framework of Interleukin (IL-)6 with the LIFR-binding site from CNTF to activate cells via IL-6R:gp130:LIFR complexes...
April 1, 2024: Journal of Biological Chemistry
https://read.qxmd.com/read/38561783/a-practical-evidence-based-approach-to-management-of-type-2-diabetes-in-children-and-young-people-cyp-uk-consensus
#22
JOURNAL ARTICLE
Billy White, S M Ng, J C Agwu, T G Barrett, N Birchmore, M Kershaw, J Drew, F Kavvoura, J Law, C Moudiotis, E Procter, P Paul, F Regan, P Reilly, P Sachdev, R Sakremath, C Semple, K Sharples, M Skae, A Timmis, E Williams, N Wright, A Soni
BACKGROUND: Type 2 diabetes in young people is an aggressive disease with a greater risk of complications leading to increased morbidity and mortality during the most productive years of life. Prevalence in the UK and globally is rising yet experience in managing this condition is limited. There are no consensus guidelines in the UK for the assessment and management of paediatric type 2 diabetes. METHODS: Multidisciplinary professionals from The Association of Children's Diabetes Clinicians (ACDC) and the National Type 2 Diabetes Working Group reviewed the evidence base and made recommendations using the Grading Of Recommendations, Assessment, Development and Evaluation (GRADE) methodology...
April 2, 2024: BMC Medicine
https://read.qxmd.com/read/38558508/immunogenicity-efficacy-and-safety-of-biosimilar-insulin-glargine-gan-lee-glargine-compared-with-originator-insulin-glargine-lantus%C3%A2-in-patients-with-type-2-diabetes-after-26%C3%A2-weeks-treatment-a-randomized-open-label-study
#23
JOURNAL ARTICLE
Elena A Christofides, Orlando Puente, Paul Norwood, Douglas Denham, Hiralal Maheshwari, Michael Lillestol, Terence Hart, Samer Nakhle, Anurekha Chadha, David Fitz-Patrick, Danny Sugimoto, Joseph Soufer, Douglas Young, Mark Warren, David Huffman, John Reed, Harold Bays, Samir Arora, Barbara Rizzardi, Raymond Tidman, Marc Rendell, Kimball A Johnson
AIM: To evaluate the equivalence of immunogenicity, safety and efficacy of Gan & Lee (GL) Glargine (Basalin®; Gan & Lee Pharmaceutical) with that of the reference product (Lantus®) in adult participants with type 2 diabetes mellitus. METHODS: This was a phase 3, multicenter, open-label, equivalence trial conducted across 57 sites. In total, 567 participants with type 2 diabetes mellitus were randomized in a 1:1 ratio to undergo treatment with either GL Glargine or Lantus® for 26 weeks...
April 1, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38554443/pd-1-receptor-t-cells-are-associated-with-the-efficacy-of-the-combined-treatment-with-regulatory-t-cells-and-rituximab-in-type-1-diabetes-children-via-regulatory-t-cells-suppressive-activity-amelioration
#24
JOURNAL ARTICLE
Maciej Zieliński, Justyna Sakowska, Dorota Iwaszkiewicz-Grześ, Mateusz Gliwiński, Matylda Hennig, Magdalena Żalińska, Anna Wołoszyn-Durkiewicz, Anna Jaźwińska-Curyłło, Halla Kamińska, Radosław Owczuk, Wojciech Młynarski, Przemysława Jarosz-Chobot, Artur Bossowski, Agnieszka Szadkowska, Wojciech Fendler, Iwona Beń-Skowronek, Agata Chobot, Małgorzata Myśliwiec, Janusz Siebert, Natalia Marek-Trzonkowska, Piotr Trzonkowski
An imbalance between exaggerated autoaggressive T cell responses, primarily CD8 + T cells, and impaired tolerogenic mechanisms underlie the development of type 1 diabetes mellitus. Disease-modifying strategies, particularly immunotherapy focusing on FoxP3 + T regulatory cells (Treg), and B cells facilitating antigen presentation for T cells, show promise. Selective depletion of B cells may be achieved with an anti-CD20 monoclonal antibody (mAb). In a 2-year-long flow cytometry follow-up, involving 32 peripheral blood T and B cell markers across three trial arms (Treg + rituximab N = 12, Treg + placebo N = 13, control N = 11), we observed significant changes...
March 29, 2024: International Immunopharmacology
https://read.qxmd.com/read/38553665/effects-of-mifepristone-on-adipocyte-differentiation-in-mouse-3t3-l1-cells
#25
JOURNAL ARTICLE
Takeshi Hashimoto, Katsuya Hirano
BACKGROUND: Both glucocorticoid receptor and peroxisome proliferator-activated receptor-γ (PPARγ) play a critical role in adipocyte differentiation. Mifepristone is not only an antagonist of the glucocorticoid receptor but also an agonist of PPARγ. Therefore, the present study investigated the effect of mifepristone on adipocyte differentiation. METHODS: Mouse 3T3-L1 cells were used as a model for adipocyte differentiation. The lipid droplet formation was evaluated with Bodipy493/503 staining and the expression of adipocyte markers [adiponectin and adipocyte fatty acid binding protein-4 (Fabp4)] was evaluated with quantitative PCR and immunoblot analyses for indication of adipocyte differentiation...
March 29, 2024: Cellular & Molecular Biology Letters
https://read.qxmd.com/read/38549041/interlaboratory-comparison-of-antibody-free-lc-ms-ms-measurements-of-c-peptide-and-insulin
#26
JOURNAL ARTICLE
Annie Moradian, Elisha Goonatilleke, Tai-Tu Lin, Maya Hatten-Beck, Michelle Emrick, Athena A Schepmoes, Thomas L Fillmore, Michael J MacCoss, Salvatore Sechi, Kimia Sobhani, Randie Little, Kuanysh Kabytaev, Jennifer E van Eyk, Wei-Jun Qian, Andrew N Hoofnagle
BACKGROUND: The enhanced precision and selectivity of liquid chromatography-tandem mass spectrometry (LC-MS/MS) makes it an attractive alternative to certain clinical immunoassays. Easily transferrable work flows could help facilitate harmonization and ensure high-quality patient care. We aimed to evaluate the interlaboratory comparability of antibody-free multiplexed insulin and C-peptide LC-MS/MS measurements. METHODS: The laboratories that comprise the Targeted Mass Spectrometry Assays for Diabetes and Obesity Research (TaMADOR) consortium verified the performance of a validated peptide-based assay (reproducibility, linearity, and lower limit of the measuring interval [LLMI])...
March 29, 2024: Clinical Chemistry
https://read.qxmd.com/read/38529494/b-cells-promote-t-cell-immunosenescence-and-mammalian-aging-parameters
#27
Saad Khan, Mainak Chakraborty, Fei Wu, Nan Chen, Tao Wang, Yi Tao Chan, Azin Sayad, Juan Diego Sánchez Vásquez, Max Kotlyar, Khiem Nguyen, Yingxiang Huang, Faisal J Alibhai, Minna Woo, Ren-Ke Li, Mansoor Husain, Igor Jurisica, Adam J Gehring, Pamela S Ohashi, David Furman, Sue Tsai, Shawn Winer, Daniel A Winer
A dysregulated adaptive immune system is a key feature of aging, and is associated with age-related chronic diseases and mortality. Most notably, aging is linked to a loss in the diversity of the T cell repertoire and expansion of activated inflammatory age-related T cell subsets, though the main drivers of these processes are largely unknown. Here, we find that T cell aging is directly influenced by B cells. Using multiple models of B cell manipulation and single-cell omics, we find B cells to be a major cell type that is largely responsible for the age-related reduction of naive T cells, their associated differentiation towards pathogenic immunosenescent T cell subsets, and for the clonal restriction of their T cell receptor (TCR)...
September 14, 2023: bioRxiv
https://read.qxmd.com/read/38524389/post-thymectomy-autoimmune-flare-up-with-new-onset-type-1-diabetes-mellitus
#28
Tareq Al-Bkoor, Fateen Ata, Ammara Bint I Bilal, Mohammed Abdulgayoom, Honar Cherif, Haval Surchi
The thymus gland aids in the maturation of the immune system. An overactive or malfunctioning thymus gland, as seen in thymomas, can lead to disrupted immune systems. Thymectomy, the usual treatment, can paradoxically lead to further derangements in the immune system, leading to new autoimmune disorders. Most of these reported disorders are rheumatological. Except preclinical studies, there are no reported cases of autoimmune diabetes post-thymectomy. A 25-year-old woman who had malignant thymoma underwent chemotherapy, followed by thymectomy and radiotherapy...
March 2024: JCEM Case Rep
https://read.qxmd.com/read/38524122/corrigendum-regulatory-t-cells-targeting-a-pathogenic-mhc-class-ii-insulin-peptide-epitope-postpone-spontaneous-autoimmune-diabetes
#29
Nyerhovwo Obarorakpor, Deep Patel, Reni Boyarov, Nansalmaa Amarsaikhan, Joseph Ray Cepeda, Doreen Eastes, Sylvia Robertson, Travis Johnson, Kai Yang, Qizhi Tang, Li Zhang
[This corrects the article DOI: 10.3389/fimmu.2023.1207108.].
2024: Frontiers in Immunology
https://read.qxmd.com/read/38523857/co-existence-of-type-1-diabetes-mellitus-and-myasthenia-gravis-a%C3%A2-case-report-and-review-of-the-literature
#30
Sabitha Sasidharan Pillai, Kate Millington
BACKGROUND/OBJECTIVE: Type 1 diabetes (T1D) and myasthenia gravis (MG) are autoimmune conditions that rarely co-occur. Here, we report a child with MG who subsequently developed T1D. CASE REPORT: An 11-year-old girl with seropositive MG diagnosed at 4 years of age presented with muscle pain, cramps, and weight loss of 3.5 kg over 4 months. Her MG was in remission on daily pyridostigmine. She denied polyuria, polydipsia, recent illnesses, or other medications...
2024: AACE Clinical Case Reports
https://read.qxmd.com/read/38519028/role-of-teplizumab-a-humanized-anti-cd3-monoclonal-antibody-in-managing-newly-diagnosed-type-1-diabetes-an-updated-systematic-review-and-meta-analysis
#31
JOURNAL ARTICLE
A B M Kamrul-Hasan, Sunetra Mondal, Lakshmi Nagendra, Ashmita Yadav, Fatema Tuz Zahura Aalpona, Deep Dutta
BACKGROUND: Teplizumab has emerged as a potential disease-modifying drug in type 1 diabetes (T1D). This meta-analysis sought to summarize the therapeutic effect of teplizumab in newly diagnosed patients with T1D. METHODS: Randomized controlled trials (RCTs) involving patients with T1D receiving teplizumab in the intervention arm and placebo (or no active intervention) in the control arm were searched throughout the electronic databases. The primary outcome was the change in area under the curve (AUC) of C-peptide levels from baseline...
March 20, 2024: Endocrine Practice
https://read.qxmd.com/read/38517484/the-innodia-type-1-diabetes-natural-history-study-a-european-cohort-of-newly-diagnosed-children-adolescents-and-adults
#32
JOURNAL ARTICLE
M Loredana Marcovecchio, A Emile J Hendriks, Carl Delfin, Tadej Battelino, Thomas Danne, Mark L Evans, Jesper Johannesen, Simranjeet Kaur, Mikael Knip, Lut Overbergh, Flemming Pociot, John A Todd, Bart Van der Schueren, Linda S Wicker, Mark Peakman, Chantal Mathieu
AIMS/HYPOTHESIS: Type 1 diabetes is an heterogenous condition. Characterising factors explaining differences in an individual's clinical course and treatment response will have important clinical and research implications. Our aim was to explore type 1 diabetes heterogeneity, as assessed by clinical characteristics, autoantibodies, beta cell function and glycaemic outcomes, during the first 12 months from diagnosis, and how it relates to age at diagnosis. METHODS: Data were collected from the large INNODIA cohort of individuals (aged 1...
March 22, 2024: Diabetologia
https://read.qxmd.com/read/38514513/beckwith-wiedemann-syndrome-with-juvenile-fibrous-nodules-and-lobular-breast-tumors-a-case-report-and-review-of-the-literature
#33
JOURNAL ARTICLE
Yo Sato, Yusuke Watanabe, Takafumi Morisaki, Saori Hayashi, Yoshiki Otsubo, Yurina Ochiai, Kimihisa Mizoguchi, Yuka Takao, Mai Yamada, Yusuke Mizuuchi, Masafumi Nakamura, Makoto Kubo
BACKGROUND: Beckwith-Wiedemann syndrome (BWS) is a genomic imprinting disorder caused by diverse genetic and/or epigenetic disorders of chromosome 11p15.5. BWS presents with a variety of clinical features, including overgrowth and an increased risk of embryonal tumors. Notably however, reports of patients with BWS and breast tumors are rare, and the association between these conditions is still unclear. Insulin-like growth factor-2 (IGF2) expression is known to be associated with the development of various cancers, including breast cancer, and patients with BWS with specific subtypes of molecular defects are known to show characteristic clinical features and IGF2 overexpression...
March 22, 2024: Surgical Case Reports
https://read.qxmd.com/read/38509534/predictive-models-of-recurrent-implantation-failure-in-patients-receiving-art-treatment-based-on-clinical-features-and-routine-laboratory-data
#34
REVIEW
Qunying Fang, Zonghui Qiao, Lei Luo, Shun Bai, Min Chen, Xiangjun Zhang, Lu Zong, Xian-Hong Tong, Li-Min Wu
STUDY QUESTION: The objective was to construct a model for predicting the probability of recurrent implantation failure (RIF) after assisted reproductive technology (ART) treatment based on the clinical characteristics and routine laboratory test data of infertile patients. A model was developed to predict RIF. The model showed high calibration in external validation, helped to identify risk factors for RIF, and improved the efficacy of ART therapy. WHAT IS KNOWN ALREADY: Research on the influencing factors of RIF has focused mainly on embryonic factors, endometrial receptivity, and immune factors...
March 20, 2024: Reproductive Biology and Endocrinology: RB&E
https://read.qxmd.com/read/38504670/severe-hyperglycemia-with-teprotumumab-for-treatment-of-thyroid-eye-disease
#35
Savannah Cottom, Brayden Barrientez, Andrew Melson
INTRODUCTION: Thyroid eye disease (TED) is a rare condition involving autoimmune-mediated inflammation of the orbit and periocular structures, which can result in many debilitating symptoms. Teprotumumab, a monoclonal antibody that targets the insulin-like growth factor 1 receptor, is gaining popularity for the treatment of TED. In fact, owing to its efficacy and side effect profile, some recommend that it be considered as a first-line therapy for patients with TED. While teprotumumab is often chosen due to its efficacy and relatively favorable side effect profile compared to other treatments, there is a known risk of hyperglycemia with this mechanism of action, which is well described through clinical trials in the oncology literature...
2024: Case Reports in Ophthalmology
https://read.qxmd.com/read/38501621/the-role-of-glutamic-acid-decarboxylases-in-diabetes-mellitus
#36
JOURNAL ARTICLE
B Azeez, I Saadoon, A Hussein
In the context of diabetes mellitus (DM), anti-glutamic acid decarboxylase (antiGAD) antibodies are associated with a specific form of the disease called type 1 diabetes. The study aims to evaluate the serum cortisol and serotonin levels in patients with type 2 DM disease. A total of 90 Iraqi participants (30 with type 1 diabetes mellitus, 30 with type 2 diabetes mellitus and 30 healthy subjects as a control group) were enrolled in the study. Blood samples were collected, serum separated, and frozen for future analysis...
January 2024: Georgian Medical News
https://read.qxmd.com/read/38500360/a-potent-neutralizing-monoclonal-antibody-to-human-growth-hormone-suppresses-insulin-like-growth-factor-1-in-female-rats
#37
JOURNAL ARTICLE
Tomoyuki Hata, Yoshikatsu Uematsu, Ayumi Sugita, Hisashi Adachi, Sayaka Kato, Maki Hirate, Kei-Ichiro Ishikura, Ayaka Kaku, Hiroki Ohara, Naoki Kojima, Teisuke Takahashi, Tomofumi Kurokawa
Acromegaly and gigantism are disorders caused by hypersecretion of growth hormone (GH), usually from pituitary adenomas. Although somatostatin analogues (SSA), dopamine agonists and GH receptor antagonist are important therapeutic agents, all of these have issues with their effectiveness, safety, and/or convenience of use. To overcome these, we developed a GH-specific potent neutralizing mouse monoclonal antibody (mAb) named 13H02. 13H02 selectively bound to both human and monkey GH with high affinity, and strongly inhibited the biological activity of GH in the Nb2 rat lymphoma cell proliferation assay...
March 19, 2024: Endocrinology
https://read.qxmd.com/read/38498418/nanomodulator-mediated-restructuring-of-adipose-tissue-immune-microenvironments-for-antiobesity-treatment
#38
JOURNAL ARTICLE
Qiaoyun Li, Junho Byun, Jaehyun Choi, Jinwon Park, Jaiwoo Lee, Yu-Kyoung Oh
In obesity, the interactions between proinflammatory macrophages and adipocytes in white adipose tissues are known to play a crucial role in disease progression by providing inflammatory microenvironments. Here, we report that the functional nanoparticle-mediated modulation of crosstalk between adipocytes and macrophages can remodel adipocyte immune microenvironments. As a functional nanomodulator, we designed antivascular cell adhesion molecule (VCAM)-1 antibody-conjugated and amlexanox-loaded polydopamine nanoparticles (VAPN)...
March 18, 2024: ACS Nano
https://read.qxmd.com/read/38493057/application-of-targeted-liposomes-based-salvianolic-acid-a-for-the-treatment-of-ischemic-stroke
#39
JOURNAL ARTICLE
Ming-Yan Yang, Yu Liu, Ya-Wen Yu, Bai-Fang Gong, Jian Ruan, Hua-Ying Fan
Novel therapeutics for the treatment of ischemic stroke remains to be the unmet clinical needs. Previous studies have indicated that salvianolic acid A (SAA) is a promising candidate for the treatment of the brain diseases. However, SAA has poor absolute bioavailability and does not efficiently cross the intact blood-brain barrier (BBB), which limit its efficacy. To this end we developed a brain-targeted liposomes for transporting SAA via the BBB by incorporating the liposomes to a transport receptor, insulin-like growth factor-1 receptor (IGF1R)...
March 15, 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38490439/extracellular-metallothionein-as-a-therapeutic-target-in-the-early-progression-of-type-1-diabetes
#40
JOURNAL ARTICLE
Clare K Melchiorre, Matthew D Lynes, Sadikshya Bhandari, Sheng-Chiang Su, Christian M Potts, Amy V Thees, Carol E Norris, Lucy Liaw, Yu-Hua Tseng, Michael A Lynes
Type 1 diabetes (T1D) is characterized by lymphocyte infiltration into the pancreatic islets of Langerhans, leading to the destruction of insulin-producing beta cells and uncontrolled hyperglycemia. In the non-obese diabetic (NOD) murine model of T1D, onset of this infiltration starts several weeks before glucose dysregulation and overt diabetes. Recruitment of immune cells to the islets is mediated by several chemotactic cytokines, including CXCL10, while other cytokines, including SDF-1α, can confer protective effects...
March 13, 2024: Cell Stress & Chaperones
keyword
keyword
83101
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.